South Africa Point-of-Care Glucose Testing Market By Product Type (Lancing Devices and Strips, Blood-Glucose Meter), By Application (Type-1 Diabetes, Type-2 Diabetes), By End User (Hospitals and Clinics, Home Care Settings, Others): Opportunity Analysis and Industry Forecast, 2023-2032

South Africa Point-of-Care Glucose Testing Market

The South Africa point-of-care glucose testing market has witnessed significant evolution over the years. Technological advancement is the prominent factor that contributes toward the growth of the South Africa point-of-care glucose testing market. The continual innovation of lancing devices and strips as well as alongside blood-glucose meters has redefined the precision and ease of glucose monitoring, enhancing the quality of care for diabetes patients. These advancements empower healthcare providers to make real-time, data-driven decisions, improving patient outcomes and reducing the burden on the healthcare system. However, economic constraints, healthcare accessibility disparities, and regulatory hurdles restrain the market growth. In addition, South Africa's economic diversity means that not all segments of the population can afford the latest glucose testing technologies, hindering universal access to cutting-edge care. Moreover, stringent regulations must be navigated by market players, contributing to compliance challenges and cost implications. On the contrary, as the prevalence of diabetes continues to rise, particularly type-2 diabetes, the demand for point-of-care glucose testing solutions escalates. South Africa's healthcare system is evolving, with a growing emphasis on value-based care and a shift toward preventive medicine. These transitions present an opportunity for market players to strengthen their foothold and offer comprehensive diabetes management solutions. 

Furthermore, the advent of connected health and the Internet of Things (IoT) promises to revolutionize glucose testing. With the integration of smartphones and wearables, patients can monitor their glucose levels seamlessly and share data with healthcare providers in real-time. Furthermore, surge in trend of personalized medicine and remote patient monitoring enhance the patient experience and treatment outcomes, which are anticipated to provide potential opportunities for the market expansion in the coming future. Furthermore, regulations are expected to evolve to accommodate the rapid advancements in glucose testing technology while ensuring patient safety and data privacy. This regulatory flexibility will encourage innovation and investment in the South Africa point-of-care glucose testing market. The South Africa point-of-care glucose testing market is segmented into product type, application, and end user. On the basis of product type, the market is bifurcated into lancing devices & strips and blood glucose meters. By application, it is divided into type-1 diabetes and type-2 diabetes. The type-2 diabetes segment dominates the market due to increase in prevalence of this condition. As lifestyle factors contribute to the rise of type-2 Diabetes, the demand for glucose testing solutions that are convenient and readily accessible continues to surge. Depending on end user, the market is segregated into hospitals & clinics, home care settings, and others. The hospitals & clinics segment is expected to exhibit highest growth, as these healthcare settings are the traditional bastions, where critical care is often administered. These institutions continue to rely on point-of-care glucose testing to manage patients effectively.  

The major players operating in the South Africa point-of-care glucose testing market are Abbott Laboratories, Roche Diagnostics, BD, Medtronic, Siemens, Nova Diabetes Care, Bayer, Cansoft Technologies, Arkray, and ACON Laboratories. These players have adopted various strategies such as R&D and pricing strategies to stay competitive in the market. 

The Porter's five forces analysis dissects the market into five key forces, providing a comprehensive view of its competitive dynamics. The market's suppliers, often manufacturers of glucose testing devices and related consumables, hold significant bargaining power. The quality and reliability of these products are paramount to patient safety and regulatory compliance, giving suppliers a strong position. On the other hand, buyers, including healthcare institutions and patients, exert their own influence. In a market teeming with alternatives, buyers can switch suppliers or devices with relative ease, placing pressure on pricing and service quality. The barriers to entry in this market are considerable. Stringent regulations and the need for substantial research and development investments to develop cutting-edge technology act as deterrents to new entrants. The threat of substitutes is notable, particularly as digital health and telemedicine solutions continue to advance. Patients can opt for remote monitoring and teleconsultations instead of in-person glucose testing, necessitating innovation to remain competitive. 

The competitive rivalry is fierce, with multiple players vying for market share. Product innovation, pricing strategies, and market positioning are key battlegrounds, driving continuous improvement and diversification. A SWOT analysis further dissects the South Africa point-of-care glucose testing market by assessing its internal strengths and weaknesses, as well as external opportunities and threats. Continuous development of user-friendly, accurate, and connected glucose testing devices; ongoing R&D efforts; segmentation to offer tailored solutions for different user needs are the key strengths of the market. However, limited access to advanced technologies due to economic disparities, stringent regulations that hinder product development and market entry, South Africa point-of-care glucose testing market, and crowded market that enforces companies to continually differentiate their offerings act as the major challenges of the market. On the contrary, rise in prevalence of diabetes, integration of glucose testing with smartphones & wearables, and evolving regulations create room for innovation and growth are expected to open new avenues for the expansion of the market during the forecast period.  Despite there are several factors that drive the market growth, the availability of substitutes such as telemedicine and remote monitoring solutions pose a threat to in-person glucose testing. In addition, economic fluctuations can impact the affordability of advanced glucose testing devices. Moreover, sudden regulatory changes can disrupt market operations and investments. 

Key players operating in the South Africa point-of-care glucose testing market include Abbott Laboratories, Roche Diagnostics, BD, Medtronic, Siemens, Nova Diabetes Care, Bayer, Cansoft Technologies, Arkray, and ACON Laboratories.

Key Benefits For Stakeholders

Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.

Analyze the key strategies adopted by major market players in South Africa point-of-care glucose testing market.

Assess and rank the top factors that are expected to affect the growth of South Africa point-of-care glucose testing market.

Top Player positioning provides a clear understanding of the present position of market players.

Detailed analysis of the South Africa point-of-care glucose testing market segmentation assists to determine the prevailing market opportunities.

Identify key investment pockets for various offerings in the market.

Additional benefits you will get with this purchase are:

● Quarterly Update and* (only available with a corporate license, on listed price)

● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

● Free Upcoming Version on the Purchase of Five and Enterprise User License.

● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)

● Free data Pack on the Five and Enterprise User License. (Excel version of the report)

● Free Updated report if the report is 6-12 months old or older.

● 24-hour priority response*

● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

● Product Benchmarking / Product specification and applications

○ ACON Laboratorie

Scope of South Africa Point-of-Care Glucose Testing Market Report

1.1. Report Description

1.2. Key Market Segments

1.3. Key Benefits to the Stakeholders

1.4. Research Methodology

1.4.1. Primary Research

1.4.2. Secondary Research

1.4.3. Analyst Tools and Models

2.1. CXO Perspective

3.1. Market Definition and Scope

3.2. Key Findings

3.2.1. Top Impacting Factors

3.2.2. Top Investment Pockets

3.3. Porter’s Five Forces Analysis

3.4. Market Dynamics

3.4.1. Drivers

3.4.2. Restraints

3.4.3. Opportunities

3.5. COVID-19 Impact Analysis on the market

4.1. Overview

4.1.1. Market Size and Forecast, By Product Type

4.2. Lancing Devices and Strips

4.3. Blood-Glucose Meter

5.1. Overview

5.1.1. Market Size and Forecast, By Application

5.2. Type-1 Diabetes

5.3. Type-2 Diabetes

6.1. Overview

6.1.1. Market Size and Forecast, By End User

6.2. Hospitals and Clinics

6.3. Home Care Settings

6.4. Others

7.1. Introduction

7.2. Top winning strategies

7.3. Product Mapping of Top 10 Player

7.4. Competitive Dashboard

7.5. Competitive Heatmap

7.6. Top player positioning, 2022

8.1. Abbott Laboratories

8.1.1. Company overview

8.1.2. Key Executives

8.1.3. Company snapshot

8.1.4. Operating business segments

8.1.5. Product portfolio

8.1.6. Business performance

8.1.7. Key strategic moves and developments

8.2. Roche Diagnostics

8.2.1. Company overview

8.2.2. Key Executives

8.2.3. Company snapshot

8.2.4. Operating business segments

8.2.5. Product portfolio

8.2.6. Business performance

8.2.7. Key strategic moves and developments

8.3. BD

8.3.1. Company overview

8.3.2. Key Executives

8.3.3. Company snapshot

8.3.4. Operating business segments

8.3.5. Product portfolio

8.3.6. Business performance

8.3.7. Key strategic moves and developments

8.4. Medtronic

8.4.1. Company overview

8.4.2. Key Executives

8.4.3. Company snapshot

8.4.4. Operating business segments

8.4.5. Product portfolio

8.4.6. Business performance

8.4.7. Key strategic moves and developments

8.5. Siemens

8.5.1. Company overview

8.5.2. Key Executives

8.5.3. Company snapshot

8.5.4. Operating business segments

8.5.5. Product portfolio

8.5.6. Business performance

8.5.7. Key strategic moves and developments

8.6. Nova Diabetes Care

8.6.1. Company overview

8.6.2. Key Executives

8.6.3. Company snapshot

8.6.4. Operating business segments

8.6.5. Product portfolio

8.6.6. Business performance

8.6.7. Key strategic moves and developments

8.7. Bayer

8.7.1. Company overview

8.7.2. Key Executives

8.7.3. Company snapshot

8.7.4. Operating business segments

8.7.5. Product portfolio

8.7.6. Business performance

8.7.7. Key strategic moves and developments

8.8. Cansoft Technologies

8.8.1. Company overview

8.8.2. Key Executives

8.8.3. Company snapshot

8.8.4. Operating business segments

8.8.5. Product portfolio

8.8.6. Business performance

8.8.7. Key strategic moves and developments

8.9. Arkray

8.9.1. Company overview

8.9.2. Key Executives

8.9.3. Company snapshot

8.9.4. Operating business segments

8.9.5. Product portfolio

8.9.6. Business performance

8.9.7. Key strategic moves and developments

8.10. ACON Laboratories

8.10.1. Company overview

8.10.2. Key Executives

8.10.3. Company snapshot

8.10.4. Operating business segments

8.10.5. Product portfolio

8.10.6. Business performance

8.10.7. Key strategic moves and development

LIST OF TABLES

TABLE 01. SOUTH AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 02. SOUTH AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 03. SOUTH AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 04. ABBOTT LABORATORIES: KEY EXECUTIVES

TABLE 05. ABBOTT LABORATORIES: COMPANY SNAPSHOT

TABLE 06. ABBOTT LABORATORIES: OPERATING SEGMENTS

TABLE 07. ABBOTT LABORATORIES: PRODUCT PORTFOLIO

TABLE 08. ABBOTT LABORATORIES: KEY STRATERGIES

TABLE 09. ROCHE DIAGNOSTICS: KEY EXECUTIVES

TABLE 10. ROCHE DIAGNOSTICS: COMPANY SNAPSHOT

TABLE 11. ROCHE DIAGNOSTICS: OPERATING SEGMENTS

TABLE 12. ROCHE DIAGNOSTICS: PRODUCT PORTFOLIO

TABLE 13. ROCHE DIAGNOSTICS: KEY STRATERGIES

TABLE 14. BD: KEY EXECUTIVES

TABLE 15. BD: COMPANY SNAPSHOT

TABLE 16. BD: OPERATING SEGMENTS

TABLE 17. BD: PRODUCT PORTFOLIO

TABLE 18. BD: KEY STRATERGIES

TABLE 19. MEDTRONIC: KEY EXECUTIVES

TABLE 20. MEDTRONIC: COMPANY SNAPSHOT

TABLE 21. MEDTRONIC: OPERATING SEGMENTS

TABLE 22. MEDTRONIC: PRODUCT PORTFOLIO

TABLE 23. MEDTRONIC: KEY STRATERGIES

TABLE 24. SIEMENS: KEY EXECUTIVES

TABLE 25. SIEMENS: COMPANY SNAPSHOT

TABLE 26. SIEMENS: OPERATING SEGMENTS

TABLE 27. SIEMENS: PRODUCT PORTFOLIO

TABLE 28. SIEMENS: KEY STRATERGIES

TABLE 29. NOVA DIABETES CARE: KEY EXECUTIVES

TABLE 30. NOVA DIABETES CARE: COMPANY SNAPSHOT

TABLE 31. NOVA DIABETES CARE: OPERATING SEGMENTS

TABLE 32. NOVA DIABETES CARE: PRODUCT PORTFOLIO

TABLE 33. NOVA DIABETES CARE: KEY STRATERGIES

TABLE 34. BAYER: KEY EXECUTIVES

TABLE 35. BAYER: COMPANY SNAPSHOT

TABLE 36. BAYER: OPERATING SEGMENTS

TABLE 37. BAYER: PRODUCT PORTFOLIO

TABLE 38. BAYER: KEY STRATERGIES

TABLE 39. CANSOFT TECHNOLOGIES: KEY EXECUTIVES

TABLE 40. CANSOFT TECHNOLOGIES: COMPANY SNAPSHOT

TABLE 41. CANSOFT TECHNOLOGIES: OPERATING SEGMENTS

TABLE 42. CANSOFT TECHNOLOGIES: PRODUCT PORTFOLIO

TABLE 43. CANSOFT TECHNOLOGIES: KEY STRATERGIES

TABLE 44. ARKRAY: KEY EXECUTIVES

TABLE 45. ARKRAY: COMPANY SNAPSHOT

TABLE 46. ARKRAY: OPERATING SEGMENTS

TABLE 47. ARKRAY: PRODUCT PORTFOLIO

TABLE 48. ARKRAY: KEY STRATERGIES

TABLE 49. ACON LABORATORIES: KEY EXECUTIVES

TABLE 50. ACON LABORATORIES: COMPANY SNAPSHOT

TABLE 51. ACON LABORATORIES: OPERATING SEGMENTS

TABLE 52. ACON LABORATORIES: PRODUCT PORTFOLIO

TABLE 53. ACON LABORATORIES: KEY STRATERGIES LIST OF FIGURES

FIGURE 01. SOUTH AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET, 2022-2032

FIGURE 02. SEGMENTATION OF SOUTH AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET, 2022-2032

FIGURE 03. TOP INVESTMENT POCKETS IN SOUTH AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET (2023-2032)

FIGURE 04. PORTER FIVE-1

FIGURE 05. PORTER FIVE-2

FIGURE 06. PORTER FIVE-3

FIGURE 07. PORTER FIVE-4

FIGURE 08. PORTER FIVE-5

FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: SOUTH AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET

FIGURE 10. SOUTH AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET,BY PRODUCT TYPE, 2022 ($MILLION)

FIGURE 11. SOUTH AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET,BY APPLICATION, 2022 ($MILLION)

FIGURE 12. SOUTH AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET,BY END USER, 2022 ($MILLION)

FIGURE 13. TOP WINNING STRATEGIES, BY YEAR

FIGURE 14. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 15. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 16. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 17. COMPETITIVE DASHBOARD

FIGURE 18. COMPETITIVE HEATMAP: SOUTH AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET

FIGURE 19. TOP PLAYER POSITIONING, 2022

FIGURE 20. ABBOTT LABORATORIES: NET SALES, 2020-2022* ($MILLION)

FIGURE 21. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 22. ABBOTT LABORATORIES: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 23. ROCHE DIAGNOSTICS: NET SALES, 2020-2022* ($MILLION)

FIGURE 24. ROCHE DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 25. ROCHE DIAGNOSTICS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 26. BD: NET SALES, 2020-2022* ($MILLION)

FIGURE 27. BD: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 28. BD: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 29. MEDTRONIC: NET SALES, 2020-2022* ($MILLION)

FIGURE 30. MEDTRONIC: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 31. MEDTRONIC: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 32. SIEMENS: NET SALES, 2020-2022* ($MILLION)

FIGURE 33. SIEMENS: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 34. SIEMENS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 35. NOVA DIABETES CARE: NET SALES, 2020-2022* ($MILLION)

FIGURE 36. NOVA DIABETES CARE: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 37. NOVA DIABETES CARE: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 38. BAYER: NET SALES, 2020-2022* ($MILLION)

FIGURE 39. BAYER: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 40. BAYER: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 41. CANSOFT TECHNOLOGIES: NET SALES, 2020-2022* ($MILLION)

FIGURE 42. CANSOFT TECHNOLOGIES: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 43. CANSOFT TECHNOLOGIES: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 44. ARKRAY: NET SALES, 2020-2022* ($MILLION)

FIGURE 45. ARKRAY: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 46. ARKRAY: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 47. ACON LABORATORIES: NET SALES, 2020-2022* ($MILLION)

FIGURE 48. ACON LABORATORIES: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 49. ACON LABORATORIES: REVENUE SHARE, BY GEOGRAPHY, 2022 (%